side effect side effect
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients who attend Urogynecology unit, Siriraj Hospital with -Nocturia patients (>1 times per night) -Age at least 55 years old -Welcomed participants
Exclusion criteria
Exclusion criteria: Patients with Neurological or psychological abnormalities History of drug allergy or side effects from melatonin Hepatic or renal dysfunction Uncontrolled diabetes mellitus, diabetes insipidus and cardiovascular disease Currently taking diuretic, tranquillizer, hypnotics or melatonin Urinary tract infection or tumor Pelvic organ prolapse at least stage 3 Pelvic organ tumor Urinary retention Currently smoking Taking medication that interact with pharmacokinetics of melatonin including carbamazepine, quinolone, rifampicin, cimetidine, estrogen
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nocturnal urination episode in nocturia patients at 2 weeks after end of taking melatonin or placebo Frequency volume chart | — |
Secondary
| Measure | Time frame |
|---|---|
| Daytime frequency episode at 2 weeks after end of taking melatonin or placebo Frequency volume chart,Night-time urine volume at 2 weeks after end of taking melatonin or placebo Frequency volume chart,24-hour urine volume at 2 weeks after end of taking melatonin or placebo Frequency volume chart,Maximal voided volume : Daytime and night-time at 2 weeks after end of taking melatonin or placebo Frequency volume chart,Thai version Nocturia Quality of Life Questionnaire score at 2 weeks after end of taking melatonin or placebo Thai version Nocturia Quality of Life Questionnaire,Side effect at 2 weeks after end of taking melatonin or placebo ascertainment | — |
Countries
Thailand
Contacts
Faculty of Medicine, Siriraj hospital, Mahidol University